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A B S T R A C T
Purpose
Medicare beneficiaries with cancer bear a greater portion of their health care costs, because
cancer treatment costs have increased. Beneficiaries have supplemental insurance to reduce
out-of-pocket costs; those without supplemental insurance may face barriers to care. This study
examines the association between type of supplemental insurance coverage and receipt of
chemotherapy among Medicare patients with cancer who, per National Comprehensive Cancer
Network treatment guidelines, should generally receive chemotherapy.
Patients and Methods
This retrospective, observational study included 1,200 Medicare patients diagnosed with incident
cancer of the breast (stage IIB to III), colon (stage III), rectum (stage II to III), lung (stage II to IV),
or ovary (stage II to IV) from 2000 to 2005. Using the National Cancer Institute Patterns of Care
Studies and linked SEER-Medicare data, we determined each Medicare patient’s supplemental
insurance status (private insurance, dual eligible [ie, Medicare with Medicaid], or no supplemental
insurance), consultation with an oncologist, and receipt of chemotherapy. Using adjusted logistic
regression, we evaluated the association of type of supplemental insurance with oncologist
consultation and receipt of chemotherapy.
Results
Dual-eligible patients were significantly less likely to receive chemotherapy than were Medicare
patients with private insurance. Patients with Medicare only who saw an oncologist had
comparable rates of chemotherapy compared with Medicare patients with private insurance.
Conclusion
Dual-eligible Medicare beneficiaries received recommended cancer chemotherapy less frequently
than other Medicare beneficiaries. With the increasing number of Medicaid patients under the
Affordable Care Act, there will be a need for patient navigators and sufficient physician
reimbursement so that low-income patients with cancer will have access to oncologists and
needed treatment.
J Clin Oncol 33:312-318. © 2014 by American Society of Clinical Oncology
INTRODUCTION
The Medicare program provides insurance coverage
to elderly Americans, reducing patient-borne ex-
penses associated with health care. However, rising
health care costs and the transition of health care
from inpatient to outpatient settings have increased
Medicare coinsurance payments and deductibles for
beneficiaries.1 For patients with cancer, medical
costs have risen over the past decade, driven in part
by ongoing development of expensive chemother-
apy drugs.2 In a recent report, cumulative 2-year
out-of-pocket spending per Medicare beneficiaries
with cancer averaged $4,727 compared with $3,209
for those without cancer.3 This cost sharing from
Medicare beneficiaries supports the financial stabil-
ity of the Medicare program but places a substantial
burden on elderly patients.
To reduce the impact of out-of-pocket costs,
most Medicare beneficiaries have supplemental
health insurance. Fee-for-service beneficiaries can
obtain supplemental insurance from the purchase of
a private (ie, Medigap) policy or from employer-
sponsored plans for their retirees. Low-income
Medicare beneficiaries may not be able to afford
supplemental policies. For some low-income bene-
ficiaries, financial assistance from Medicaid can off-
set these costs. Approximately 20% of Medicare
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beneficiaries are dually eligible for Medicare and Medicaid, with Med-
icaid serving as the supplemental coverage.4 Dual-eligible beneficiaries
may encounter challenges in accessing care. Prior studies have dem-
onstrated that Medicaid recipients of all ages are less likely to obtain
recommended care compared with those who are privately insured.5-7
Medicare patients who do not have Medicaid or supplemental private
insurance face significant out-of-pocket expenses. Medicare patients
with no supplemental insurance have been reported to receive less
cancer treatment.8
In this study, we examined the relationship between supple-
mental insurance coverage and the receipt of chemotherapy
among Medicare beneficiaries. The study included patients with
selected cancers who, based on their cancer site and stage, should
generally receive chemotherapy per National Comprehensive Cancer
Network (NCCN) treatment guidelines.9-13 We sought to determine
whether the type of supplemental insurance was related to disparities
in the receipt of chemotherapy. We hypothesized that Medicare pa-
tients with no supplemental insurance or those dually eligible for
Medicaid may receive less recommended chemotherapy than those
with private supplemental insurance.
PATIENTS AND METHODS
Data Sources
The National Cancer Institute (NCI) SEER cancer registries collect in-
formation on all incident cancers occurring in 17 defined geographic regions
and are generally representative of the US population. The population-based
SEER data, collected primarily from hospital records, include date of
diagnosis, tumor site and stage, initial treatment, and selected demo-
graphic characteristics for each patient. Chemotherapy is under-reported
in SEER data, because most systemic therapies are provided in the outpa-
tient setting. To obtain information on chemotherapy use, NCI annually
conducts Patterns of Care (POC) studies on a subset of SEER patients with
selected cancer sites. The specific cancers vary by year. POC studies collect
information from the medical records of patients with cancer about treat-
ment, comorbidities, and type of health insurance.14 Each SEER registry
obtains institutional review board approval as required before initiating
the study.
NCI also sponsors the SEER-Medicare data, a linkage of patients in the
SEER data with their Medicare enrollment and claims files. Of patients in SEER
registries age  65 years, 94% have been linked to the Medicare master
enrollment file.15 Medicare enrollment data include monthly indicators about
health maintenance organization enrollment or whether the beneficiary re-
ceives state buy-in (SBI) assistance, a proxy for Medicaid enrollment. For
beneficiaries with fee-for-service coverage, a Medicare claim includes a vari-
able indicating if Medicare is the secondary payer to a primary insurer for that
claim. Medicare physician and outpatient claims include procedure codes that
describe the services billed on each claim, each physician’s unique provider
identification number (UPIN), and the physician’s specialty. The NCI
POC data and SEER-Medicare data include a unique SEER case number
for each patient that was used to match persons in the POC data to the
SEER-Medicare data.
Study Population
The POC study population included a subset of patients reported in the
SEER data with an incident diagnosis. Cancer sites varied, because the POC
studies include different cancer sites each year. Our analysis included patients
with stage IIB to III breast, stage III colon, and stage II to III rectal cancers in
2000 and 2005; stage II to IV non–small-cell lung cancer in 2005; and stage II to
IV ovarian cancer in 2002. We included the most recent years of data available
for the specific sites.
Patients with a prior cancer diagnosis, a simultaneous second cancer
diagnosis, or cancer reported only by autopsy or death certificate were ineligi-
ble for the POC study. Eligible patients were stratified by registry, sex, and
racial/ethnic group and then randomly sampled within strata. Sampling
weights varied based on the sex and race/ethnicity of the patient. Sampling
fractions were used to calculate weighted percentages, reflecting the SEER
populations from which the data were obtained. Women, non-Hispanic
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Fig 1. Steps to determine if Medicare beneficiaries had private insurance or Medicaid. FFS, fee for service; MSP, Medicare is secondary payer to private insurance;
POC, Patterns of Care; SBI, state buy-in.
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blacks, Hispanics, Asians/Pacific Islanders, American Indians, and Native
Alaskans were oversampled to obtain more stable estimates. From the POC
data, we identified persons age  65 years who also appeared in the
SEER-Medicare data. To ensure complete data from the Medicare files,
patients were required to have had continuous Medicare Part A (hospital
insurance) and Part B (medical insurance) and fee-for-service coverage
in the 6 months after diagnosis. Patients were not required to have
undergone surgery for their cancer, because surgery was not indicated
for all of the cancers.
Medicare Supplemental Insurance Definitions
Supplemental insurance status was determined from the POC and
SEER-Medicare data, as shown in Figure 1. We classified each patient’s insur-
ance information into one of three categories: Medicare with private insur-
ance, Medicare only, or Medicare and Medicaid, also known as dual-eligible
patients. From the POC data, private insurance was defined as any insurance
provided by a private insurance company, government insurance other than
Medicare or Medicaid (eg, Tricare, Veterans Affairs, other military), Blue
Cross/Blue Shield, or other similar insurance types. Medicaid eligibility was
assigned if the patient was identified as having Medicaid. The Medicare-only
designation included patients who were reported as having no insurance other
than Medicare.
For patients who had no supplement insurance identified in the POC
data, we used the SEER-Medicare data to search for additional information
about insurance. Medicare claims include a variable—primary payer
amount—noting if there is a primary payer other than Medicare. This occurs
when Medicare beneficiaries or their spouses are still working and are covered
through an employer’s health insurance plan. Patients were considered to have
a private insurer in addition to Medicare if the primary payer amount variable
on any Medicare claims during the 6 months after the date of diagnosis
included any value  $0. We used the SBI variable from the Medicare data.
Medicare buy-in benefits, operated by state Medicaid programs, help
low-income Medicare beneficiaries pay their Medicare premiums, deduct-
ibles, and copayments. If the SBI variable was flagged during the calendar
year of diagnosis, the patient was assigned as having Medicaid in addition
to having Medicare.
Assessment of Receipt of Chemotherapy and Consultation
With Oncologist
Information about whether a patient had received chemotherapy was
collected in the POC study from a patient’s treating physician. Chemotherapy
receipt was limited to initial treatment, generally regarded as treatment
planned or administered before progression or disease recurrence.
Our focus was on the receipt of chemotherapy. However, oncologists
are key decision makers about chemotherapy administration. Therefore,
we evaluated whether consultation with an oncologist varied by supple-
mental insurance status. Oncologists were identified by matching UPINs
for the physicians from the SEER-Medicare claims to American Medical














No. % No. % No. % No. %
Age group, years
65-69 283 21.5 138 24.5 62 11.9 83 26.2
70-74 303 25.3 133 25.9 72 24.1 98 25.5
75-79 284 24.8 122 21.7 84 33.4 78 22.0
80-84 195 17.8 100 18.3 44 16.9 51 17.5
 85 135 10.6 56 9.6 42 13.7 37 8.8
Race
Non-Hispanic white 578 80.3 357 90.2 165 82.1 56 44.1
Non-Hispanic black 269 9.1 94 5.4 71 8.7 104 22.2
Hispanic 161 4.6 49 1.9 37 4.5 75 14.1
Asian/Pacific Islander 181 5.9 45 2.4 29 4.6 107 19.5
American Indian† 11 0.1  11 —  11 —  11 —
Marital status
Married 577 51.2 303 58.8 146 44.1 128 36.8
Unmarried 623 48.8 246 41.2 158 55.9 219 63.2
Cancer site and stage
Breast IIB-III 120 19.4 62 23.0 23 12.2 35 18.5
Colon III 234 12.2 108 11.6 59 14.4 67 10.8
Rectal II-III 301 17.7 124 15.7 89 22.1 88 17.3
NSCLC II-IV 288 45.2 125 43.9 60 45.9 103 48.8
Ovarian II-IV 257 5.5 130 5.8 73 5.5 54 4.6
Charlson comorbidity score
0 772 59.2 360 59.1 205 62.9 360 59.1
1 313 29.3 139 29.1 72 26.2 139 29.1
 2 115 11.6 50 11.8 27 11.0 50 11.8
Prediagnosis physician visit in nursing home
No 1,156 96.3 542 98.5 294 96.7 324 92.5
Yes 44 3.7  11 —  11 — 23 7.5
Abbreviation: NSCLC, non–small-cell lung cancer
Weighted.
†Exact cell sizes  11 are suppressed to protect patient confidentiality.
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Association (AMA) data on physician specialty. If the patient had a claim
from a physician whose primary or secondary specialty was hematology/
oncology or medical oncology in the AMA data, the patient was classified
as having had an oncology consultation. If the physician’s UPIN was not
matched to the AMA data, the physician specialty on each patient’s Medi-
care claim was used to determine if the patient had seen an oncologist.
Statistical Analysis
Multivariable logistic regression models were used to assess the associa-
tion between receipt of oncologist consultation and chemotherapy by supple-
mental insurance type. Two models were used with binary dependent variables
(yes v no) for oncologist consultation and receipt of chemotherapy, respec-
tively. Oncologist consultation was hypothesized to modify the effect of insur-
ance type on receipt of chemotherapy, and this was tested with an interaction
term in the second model and included in the second model along with the
main effects. The results of the logistic regression analyses were presented as
standardized percentages (predictive margins), representing the average per-
cent of patients consulting with an oncologist or receiving chemotherapy.16
Cancer sites were combined to increase sample size. To control for differences
in patients in each of the three insurance categories, the standardized percent-
ages and SEs were adjusted for supplemental insurance type, cancer site and
stage, race, age, marital status, Charlson comorbidity score, and whether the
patient was in a nursing home during the 3 months before the cancer diagno-
sis, using an established algorithm based on procedure codes for nursing home
visits reported in the physician claims.17 Information about income and edu-
cational level for the US Census tract where the patient lived was assessed in
earlier models but not included in the final model, because the variables
were not significantly associated with oncologist consultation or receipt of
chemotherapy. We used SUDAAN statistical software (Research Triangle
Institute, Research Triangle Park, NC) to account for the sampling design
in all analyses.
RESULTS
Of the 1,200 patients in our study, 45.8% had Medicare with
private insurance, 25.3% had Medicare only, and 28.9% had Medi-
care and Medicaid (Table 1). Supplemental insurance status varied
by age, race, and marital status. The oldest beneficiaries—those age
 85 years—accounted for 13.7% of patients with Medicare only,
although they accounted for 10.6% of all patients with cancer.
Non-Hispanic black patients composed 22.2% of dual-eligible pa-
tients, although they accounted for 9.1% of all patients. Dual-
eligible patients had more physician nursing home visits (7.5%)
than did Medicare-only patients (3.3%) or those with Medicare
and private insurance (1.5%).
All patients in the sample had a cancer site and stage where
chemotherapy would generally be indicated per NCCN guidelines.
Only 52.5% of all patients received chemotherapy (Table 2). Although
 80% of the sample had a consultation with an oncologist,  60% of
those who saw an oncologist received chemotherapy. Chemotherapy
use varied by cancer site; patients with rectal cancer having the greatest
use of chemotherapy (63.6%), whereas those with lung cancer had the
lowest use of chemotherapy (48.7%).
The standardized percentage of patients who saw an oncologist
or received chemotherapy varied by type of supplemental insurance. A
lower percentage of dual-eligible Medicare and Medicaid patients saw
oncologists than did patients who had Medicare with private insur-
ance (78.4% and 83.6%, respectively; Table 3). However, patients of
any insurance type who saw an oncologist received chemotherapy
more often compared with those with no oncology consultation,
although this difference was not statistically significant (interaction P
 .55). Dual-eligible patients received chemotherapy significantly less
often than did patients who had Medicare with private insurance,
regardless of whether they had an oncologist consultation. Only 44.2%
of dual-eligible patients who had an oncology consultation received
chemotherapy, compared with 60.8% of those with Medicare and
private insurance. Patient age was also a significant factor for receipt of
chemotherapy, with patients age  75 years significantly less likely to
receive chemotherapy than younger patients. Receipt of chemother-
apy varied significantly by cancer site and stage, with patients with
Table 2. Patient Comorbidity, Consultation With Oncologist, and Receipt of Chemotherapy by Cancer Type
Variable
All Patients
Cancer Site and Stage
Breast IIB







No. % No. % No. % No. % No. % No. %
Oncologist consultation
Yes 946 81.5 102 80.7 186 81.9 232 80.2 235 83.4 191 73.0
No 254 18.5 18 19.3 48 18.1 69 19.8 53 16.7 66 27.0
Received chemotherapy†
Yes 676 52.5 53 47.9 125 54.5 185 63.6 147 48.7 166 59.1
No 524 47.6 67 52.1 109 45.5 116 36.5 141 51.3 91 40.9
Received chemotherapy‡
Yes 608 59.8 50 54.6 118 63.6 172 74.8 139 54.9 129 63.8
No 338 40.2 52 45.4 68 36.4 60 25.2 96 45.1 62 36.2
Charlson comorbidity score
0 772 59.2 83 67.5 146 64.6 200 66.2 145 49.0 198 78.5
1 313 29.3 29 29.8 66 30.0 74 26.7 97 31.3 47 17.3
 2 115 11.6 8 2.7 22 5.5 27 7.1 46 19.7 12 4.2
Abbreviation: NSCLC, non–small-cell lung cancer.
Weighted.
†All patients.
‡Among patients with oncologist consultation.
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stage II to IV lung cancer or stage IIB to III breast cancer significantly
less likely to receive chemotherapy than those with colon, rectal, or
ovarian cancer. Patients with a prediagnosis nursing home claim were
significantly less likely (15.9%) to receive chemotherapy than were
patients with no nursing home claims (53.0%).
DISCUSSION
This analysis assessed the association between supplemental health
insurance and receipt of chemotherapy among Medicare patients with
cancer for whom chemotherapy is generally recommended per guide-
lines. We found that dual-eligible patients had significantly lower
receipt of chemotherapy than did Medicare patients with cancer who
had private supplemental coverage, whether or not they had an oncol-
ogy consultation and accounting for differences between the two
groups, including cancer site, stage, age, race, comorbidities, and
whether the patient was in a nursing home before diagnosis. The
reasons for these lower rates of treatment are not entirely apparent,
because both groups had Medicare and additional insurance to cover
copayments and deductibles.
There may be health care system and patient factors that influ-
enced treatment decisions. We examined consultation with an oncol-
ogist as one factor related to treatment. Oncology consultations
among dual-eligible patients were 8% lower than those for Medicare
patients with private supplemental insurance. This difference may
reflect challenges encountered by dual-eligible patients in finding an
oncologist to care for them. Reduced government payments to physi-
cians have resulted in an increasing number of physicians declining to
treat Medicare and Medicaid patients. A 2012 survey of physicians
reported that 25% were not accepting new Medicare patients, and
36% were not accepting new Medicaid patients.18 For dual-eligible
patients, states have been required to cover their Medicare copay-
ments. However, states have been allowed to limit their obligation
to the Medicaid rate of the state. As a result, many physicians are
not reimbursed for patient cost sharing, affecting physicians’ fi-
nancial ability to accept dual-eligible patients. Physicians’ willing-
ness to accept dual-eligible patients is a particular concern, given
the projected shortage of oncologists.19 With patient demand ex-
ceeding supply, oncologists may limit the types of insurance they
are willing to accept.
The expansion of Medicaid under the Affordable Care Act (ACA)
will increase the number of Medicare patients with cancer who are
eligible for Medicaid. Under the ACA, state Medicaid programs will be
required to pay medical oncologists any cost sharing for Medicare
patients receiving evaluation and management physician services.20
Physicians have reported willingness to take more Medicaid patients if
reimbursement were increased, although they have been found to
perceive Medicaid patients as being needier and more likely to be
noncompliant.21 Future evaluation is needed to determine whether
coverage by Medicaid of cost sharing for dual-eligible patients will
alter physicians’ acceptance of such patients.
There are other possible explanations for the lower rate in che-
motherapy use found between dual-eligible patients and patients who
had Medicare with private insurance. Dual-eligible patients may not
be good candidates for chemotherapy; they have been reported to have
more chronic conditions and cognitive or mental impairment when
compared with other Medicare beneficiaries.4 In our study, comor-
bidity scores were comparable across insurance groups. Nursing
home visits were higher among dual-eligible patients, although in the
adjusted models, this did not explain the lower use of chemotherapy
among the dual-eligible population. The type of hospital where pa-
tients were treated may have influenced the lower rate of chemother-
apy among dual-eligible patients. Patients treated in larger teaching
hospitals have been found to receive more adjuvant therapy, regard-
less of type of insurance.22 However, Medicaid patients with cancer
have been reported to be more likely to receive care in low-volume
hospitals,23 where there may be less use of chemotherapy. Lower
rates of chemotherapy use in the dual-eligible patients may reflect








% SE % SE
Supplemental insurance
category†
Medicare plus private‡ 83.6 2.3 60.8 3.8
Medicare only 79.3 4.3 60.0 5.2
Medicare plus Medicaid 78.4 4.8 44.2 5.8
Supplemental insurance
category§
Medicare plus private‡ 32.4 7.8
Medicare only 16.9 8.8
Medicare plus Medicaid 14.7 5.7
Age group, years
65-69‡ 87.9 3.5 70.9 4.4
70-74 85.4 3.4 59.0 5.3
75-79 81.5 4.1 51.1 4.7
80-84 78.1 4.2 38.4 6.1
 85 62.6 6.3 22.0 5.9
Charlson comorbidity score
0‡ 84.5 2.1 56.1 3.3
1 76.9 4.0 45.1 5.0
 2 76.8 7.7 52.8 6.6
Cancer site and stage
Breast IIB to III‡ 77.0 5.9 44.0 6.7
Colon III 85.2 2.8 61.0 3.8
Rectal II to III 80.3 2.8 64.0 3.8
Lung II to IV 84.0 2.8 48.6 4.2
Ovary II to IV 69.9 4.2 59.9 4.6
Race
Non-Hispanic black‡ 79.2 3.6 49.2 4.6
Hispanic 4.6 69.8 59.3 5.2
Non-Hispanic white 82.5 2.3 52.6 3.1
Asian/Pacific Islander 8.5 53.4 50.3 5.7
American Indian/Native
Alaskan 11.9 42.2 66.2 29.4
Marital status
Married‡ 78.6 3.1 54.5 3.5
Unmarried 84.1 2.2 50.4 3.8
Prediagnosis physician visit
in nursing home
No‡ 82.8 1.9 53.0 2.7
Yes 41.0 14.0 15.9 6.4
NOTE. Bold font indicates statistical significance (P  .05).
Standardized percentages adjusted for all other variables in table.
†Among those with oncologist consultation.
‡Reference group in logistic regression model.
§Among those without oncologist consultation.
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Medicaid patients having different perspectives about chemother-
apy than patients with Medicare with private insurance. Our data
do not have detailed information about patient or provider treat-
ment preferences.
We hypothesized that patients with Medicare only would be less
likely to see an oncologist and receive chemotherapy because of con-
cerns about out-of-pocket payments. We found lower consultation
with an oncologist for patients with Medicare only compared with
patients with Medicare with private insurance. However, receipt of
chemotherapy was similar for patients with Medicare only and those
with Medicare with private insurance. The growing use of oral chemo-
therapeutic agents will greatly increase the copayment burden for
patients with Medicare only.24 There needs to be ongoing assessment
of the use of chemotherapy among patients with Medicare only.
Among patients in our study, approximately half were not receiv-
ing chemotherapy, despite NCCN guidelines generally recommend-
ing chemotherapy for these patients and  80% having a consultation
with an oncologist. The rate of nontreatment in our study was higher
than the 9% to 12% nontreatment rate reported from a study using
data from the National Cancer Data Base and Iowa Cancer Registry.25
The earlier study included patients of all ages. In contrast, our analysis
was limited to elderly persons. Our findings, especially that persons
age  75 years and those in nursing homes were significantly less likely
to receive treatment, suggest that patients and physicians are consid-
ering life expectancy when deciding about whether to refer a patient to
an oncologist or to recommend chemotherapy.
This study of the Medicare population is novel in that it exam-
ined how type of supplemental insurance is associated with cancer
treatment. Although the question addresses a gap in the literature,
there are limitations to our analysis. The findings from the SEER
population may not be generalized to the entire US population. Our
study group included a higher percentage of dual-eligible patients and
patients with Medicare only than reported in the general Medicare
population.26 We relied on information reported in the medical re-
cords, augmented with information from Medicare, to determine type
of supplemental coverage. If this information was missing or inaccu-
rately reported, this would influence our findings. For example, the
sensitivity of the Medicare SBI variable is suboptimal.27 We also relied
on identification of oncologists based on physician number from
Medicare data. Patients may have received chemotherapy from other
medical specialists, such as gynecologists or surgeons. This may ex-
plain why patients with ovarian cancer had a lower percentage of
oncology consultations but a similar rate of chemotherapy use.
In conclusion, this study demonstrates that for elderly patients
with cancer, being eligible for Medicare does not guarantee receipt of
cancer treatment. The most vulnerable of the Medicare population—
low-income dual-eligible patient—are receiving less cancer treatment
than are other Medicare beneficiaries. Programs to provide patient
navigators for dual-eligible patients with cancer may help them access
the system. In addition, ensuring adequate physician reimbursement
so that there are a sufficient number of physicians willing to treat
Medicaid patients is an important consideration, especially because
the number of Medicaid patients will increase under the ACA.
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